Inmune Bio (INMB) Common Equity (2017 - 2026)
Inmune Bio (INMB) posted Common Equity of $19.6 million for Q1 2026, down 16.58% sequentially from $23.5 million in Q4 2025, and down 33.87% YoY from $29.7 million in Q1 2025.
Inmune Bio (INMB) Common Equity (2017 - 2026) Analysis & Trends
Inmune Bio has reported Common Equity for 10 years, with the latest figure at $19.6 million in Q1 2026.
- Quarterly Common Equity fell 33.87% year-over-year to $19.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.6 million (down 33.87% YoY) and the FY2025 annual result came in at $23.5 million, down 26.71% from the prior year.
- Common Equity slipped to $19.6 million in Q1 2026 per INMB's latest filing, from $23.5 million in the prior quarter.
- Over five years, Common Equity peaked at $75.6 million in Q1 2022 and troughed at $19.6 million in Q1 2026.
- A 5-year average of $42.3 million and a median of $37.3 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2024: Common Equity surged 61.76% in 2022, then sank 48.96% in 2024.
- Over 5 years, Common Equity stood at $60.1 million in 2022, then tumbled by 37.87% to $37.3 million in 2023, then fell by 14.04% to $32.1 million in 2024, then retreated by 26.71% to $23.5 million in 2025, then dropped by 16.58% to $19.6 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $19.6 million, $23.5 million, and $25.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | 20.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.36 Mn |
| Mar 31, 2026 | 19.62 Mn |
| Dec 31, 2025 | 23.52 Mn |
| Sep 30, 2025 | 25.38 Mn |
| Jun 30, 2025 | 28.87 Mn |
| Mar 31, 2025 | 29.67 Mn |
| Dec 31, 2024 | 32.10 Mn |
| Sep 30, 2024 | 38.68 Mn |
| Jun 30, 2024 | 36.28 Mn |
| Mar 31, 2024 | 28.22 Mn |
| Dec 31, 2023 | 37.34 Mn |
| Sep 30, 2023 | 43.93 Mn |
| Jun 30, 2023 | 50.65 Mn |
| Mar 31, 2023 | 55.30 Mn |
| Dec 31, 2022 | 60.10 Mn |
| Sep 30, 2022 | 63.71 Mn |
| Jun 30, 2022 | 69.93 Mn |
| Mar 31, 2022 | 75.64 Mn |
| Dec 31, 2021 | 80.23 Mn |
| Sep 30, 2021 | 88.26 Mn |